BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dapagliflozin: Phase III data

A double-blind Phase III trial in 814 patients with Type II diabetes inadequately controlled with metformin showed that dapagliflozin plus metformin met the primary endpoint of non-inferiority to glipizide plus metformin in change from baseline in HbA1c at week 52 (0.52% for both). Dapagliflozin plus metformin also met the secondary endpoint of significantly reducing weight loss from baseline to week 52 vs. glipizide plus metformin (3.22 kg...

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >